| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/09/2003 | US6617317 Boronic ester and acid compositions |
| 09/09/2003 | US6617307 Useful for treatment of fractures, as a filler in deficient sites of bone, for inhibition of decrease in bone substance related to osteoporosis and periodontic diseases |
| 09/09/2003 | US6616943 Composition comprising Wenguanguo extracts and methods for preparing same |
| 09/09/2003 | CA2263566C Substituted 6,5-hetero-bicyclic derivatives |
| 09/04/2003 | WO2003073062A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/04/2003 | WO2003072787A2 Method for detection of leptin receptor ligands |
| 09/04/2003 | WO2003072780A1 Novel proteins, dnas thereof and use of the same |
| 09/04/2003 | WO2003072779A1 Method of using pituitary-specific genes |
| 09/04/2003 | WO2003072720A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 09/04/2003 | WO2003072719A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences |
| 09/04/2003 | WO2003072715A2 Gasp1: a follistatin domain containing protein |
| 09/04/2003 | WO2003072714A2 Follistatin domain containing proteins |
| 09/04/2003 | WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/04/2003 | WO2003072577A1 Thiazole derivatives as npy receptor antagonists |
| 09/04/2003 | WO2003072569A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| 09/04/2003 | WO2003072557A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 09/04/2003 | WO2003072556A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | WO2003072544A1 Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine |
| 09/04/2003 | WO2003072528A2 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 09/04/2003 | WO2003072135A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 09/04/2003 | WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072109A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones |
| 09/04/2003 | WO2003072097A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/04/2003 | WO2003072062A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| 09/04/2003 | WO2003072060A2 Polypeptide formulation |
| 09/04/2003 | WO2003072035A2 Compositions and methods for the treatment of immune related diseases |
| 09/04/2003 | WO2003072027A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 09/04/2003 | WO2003071991A1 Tissue repair matrix |
| 09/04/2003 | WO2003051805A3 Substituted phenyl naphthalenes as estrogenic agents |
| 09/04/2003 | WO2003045313A3 2-aminoquinoline compounds |
| 09/04/2003 | WO2003032961A3 Methods for preventing and treating bone loss with steroid compounds |
| 09/04/2003 | WO2003030922A3 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 09/04/2003 | WO2003029283A3 Genetic sequences related to bone diseases in the osteopetrotic grey-lethal (gl) mouse |
| 09/04/2003 | WO2002088106A3 Cysteine protease inhibitors |
| 09/04/2003 | WO2002079248A3 Mammalian alpha-helical protein-53 |
| 09/04/2003 | WO2002079238A3 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis |
| 09/04/2003 | WO2002070468A3 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity |
| 09/04/2003 | WO2002064792A3 Molecules for disease detection and treatment |
| 09/04/2003 | WO2002055698A3 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 09/04/2003 | WO2002055016A3 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS |
| 09/04/2003 | WO2002020769A9 Human and mouse targeting peptides identified by phage display |
| 09/04/2003 | WO2001057261A9 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 09/04/2003 | WO2000067776A9 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 09/04/2003 | US20030167525 Desaturase genes and uses thereof |
| 09/04/2003 | US20030166989 Method of radiotherapy |
| 09/04/2003 | US20030166910 Bone morphogenic protein |
| 09/04/2003 | US20030166902 Hybrid; process control; genetic engineering |
| 09/04/2003 | US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents |
| 09/04/2003 | US20030166872 Grafting antibodies to nucleic acids; anticancer agents, osteoporosis, vision defects, antiinflammatory agents, skin disorders |
| 09/04/2003 | US20030166859 Controlling cell proliferation, cell differentiation; anticancer agents |
| 09/04/2003 | US20030166838 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives |
| 09/04/2003 | US20030166730 Amide derivatives for the treatment of diseases mediated by cytokines |
| 09/04/2003 | US20030166725 Compounds active at the glucocorticoid receptor |
| 09/04/2003 | US20030166706 Method of treating osteoarthritis |
| 09/04/2003 | US20030166689 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/04/2003 | US20030166685 Acid derivatives of benzene useful as anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer |
| 09/04/2003 | US20030166671 Amorphous polymorphic forms by grinding or pulverizing; having a distinctive X-ray powder diffraction pattern; anti-tumor and -carcinogenic agents; administered by mouth, intravenous injection and inhalation |
| 09/04/2003 | US20030166668 Substituted heteroarylalkanoic acids |
| 09/04/2003 | US20030166652 Chemical compounds |
| 09/04/2003 | US20030166646 Nitric oxide synthase inhibitors such as 4-(morpholin-4-yl methyl)-4,5-dihydro-1,3-thiazol-2-ylamine, administered for prophylaxis of neurodegenerative diseases |
| 09/04/2003 | US20030166633 Pyridinylimidazoles |
| 09/04/2003 | US20030166631 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists |
| 09/04/2003 | US20030166628 Drugs such as 3-(4-chlorobenzo(b)thiophen-2-yl)-5,6-dihydro-imidazo(2,1-b)thiazole, used as hydroxytryptamine and/or noradrenaline reuptake inhibitors; anxiolytic agents |
| 09/04/2003 | US20030166613 A macrocyclic diterpene plant extract for treating viral infections; A computer program product for storing the library information of candidate compounds |
| 09/04/2003 | US20030166589 Method and pharmaceutical composition for the treatment of multiple sclerosis |
| 09/04/2003 | US20030166559 Comprises tumor necrosis factor antagonist activity for treatment of autoimmune conditions |
| 09/04/2003 | US20030166556 Immunoregulator |
| 09/04/2003 | US20030166546 Uses of THANK, a TNF homologue that activates apoptosis |
| 09/04/2003 | US20030166538 Isolated inflammation-related gene, the protein molecule encoded by the gene, and the use of the gene in diagnosis and treatment of inflammatory conditions. |
| 09/04/2003 | US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide |
| 09/04/2003 | US20030166300 Growth-related inflammatory and immune response protein |
| 09/04/2003 | US20030166257 Use of Lactobacillus salivarius |
| 09/04/2003 | US20030166247 Transforming growth factor binding proteins; fusion proteins; knockout animal models; for treatment of osteoporosis/ fractures |
| 09/04/2003 | US20030166239 Bone morphogenic proteins; for regulating bone homeostasis, adiposity, and calcification of atherosclerotic plaques |
| 09/04/2003 | US20030166140 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide polyadenylation sequence all |
| 09/04/2003 | US20030166044 Novel proteins |
| 09/04/2003 | US20030166024 Nucleotide sequences coding monoclonal antibody for the prevention, treatment and diagnosis of viral, inflammatory and tumor diseases; gene therapy |
| 09/04/2003 | US20030165928 Susceptibility to bone damage |
| 09/04/2003 | US20030165818 Detecting modulators of serine protease/dipeptidyl peptidase activity for treating viral/muscular/bone/nervous system disorders |
| 09/04/2003 | US20030165569 Composition for topical substance delivery |
| 09/04/2003 | US20030165499 Compositions and methods for treating psoriasis |
| 09/04/2003 | US20030165460 Proteins which control cell differentiation; immunology response; antiinflammatory agents; wound healing agents |
| 09/04/2003 | CA2743750A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus |
| 09/04/2003 | CA2479812A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | CA2477634A1 Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine |
| 09/04/2003 | CA2477347A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/04/2003 | CA2477235A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| 09/04/2003 | CA2477234A1 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
| 09/04/2003 | CA2477008A1 Substituted pyrimidinones and pyrimidinthiones |
| 09/04/2003 | CA2476896A1 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 09/04/2003 | CA2476887A1 Gasp1:a follistatin domain containing protein |
| 09/04/2003 | CA2476846A1 Method for detection of leptin receptor ligands |
| 09/04/2003 | CA2476654A1 Follistatin domain containing proteins |
| 09/04/2003 | CA2476630A1 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof |
| 09/04/2003 | CA2476518A1 Compositions and methods for the treatment of immune related diseases |
| 09/04/2003 | CA2475653A1 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 09/04/2003 | CA2475299A1 Thiazole derivatives as npy receptor antagonists |
| 09/04/2003 | CA2459155A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/03/2003 | EP1340815A2 Determination of alpha-N-acetylgalactosaminidase activity |